|Bid||228.00 x 800|
|Ask||339.89 x 800|
|Day's Range||236.30 - 242.25|
|52 Week Range||208.62 - 265.87|
|Beta (3Y Monthly)||1.32|
|PE Ratio (TTM)||403.47|
|Earnings Date||Feb 5, 2019|
|Forward Dividend & Yield||3.08 (1.36%)|
|1y Target Est||265.05|
Amid heightened volatility and uncertainty, investors are looking for both income and growth in their portfolio. As a result, picking dividend growth stocks appear as a winning strategy.
How far off is Becton, Dickinson and Company (NYSE:BDX) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock Read More...
Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.
said it expects fiscal first-quarter results above Wall Street's expectations. The multinational medical technology company expects quarterly revenue of $4.16 billion for the first fiscal quarter ended Dec. 31, an increase of 35.1% from the prior year, primarily due to the acquisition of C. R. Bard, the company said. Preliminary earnings per share of $2.70 increased 8.9% from $2.48 the prior year, or 14.9% on a currency-neutral basis.
Becton Dickinson & Co. said it expects to swing to fiscal first-quarter net earnings per share of $2.05, from a loss of 76 cents in the same period a year ago. Excluding non-recurring items, adjusted EPS is expected to rise to $2.70 from $2.48, above the FactSet consensus of $2.59. Revenue is expected to rise 35% to $4.16 billion, topping the FactSet consensus of $4.11 billion. The medical technology company affirmed its 2019 revenue growth outlook of 8.5% to 9.5%, and its adjusted EPS guidance of $12.05 to $12.15. The stock, which was still inactive in premarket trade, has lost 5.6% over the past three months, while the SPDR Health Care Select Sector ETF has declined 5.5% and the S&P 500 has given up 6.9%.
- Preliminary reported revenues of $4.160 billion increased 35.1 percent. - On a comparable, currency-neutral basis, preliminary revenues increased 5.2 percent. - As reported, preliminary diluted earnings ...
FRANKLIN LAKES, N.J. , Jan. 15, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will host a live webcast of its Annual ...
# Becton Dickinson and Co ### NYSE:BDX View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for BDX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $14.29 billion over the last one-month into ETFs that hold BDX are among the highest of the last year, but the rate of growth is slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. BDX credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
FRANKLIN LAKES, N.J. , Jan. 8, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2019 earnings conference ...
According to GuruFocus' list of 52-week lows, these Guru stocks have reached their 52-week lows. The price of Becton, Dickinson and Co. (BDX) shares has declined to close to the 52-week low of $216.99, which is 21.5% off the 52-week high of $265.87. The company has a market cap of $58.47 billion.
Pharmaceutical companies in the Triangle were far from exempt from a worldwide dive in stock prices, with some companies sliding more than 50 percent.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 26) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Down In The ...
FRANKLIN LAKES, N.J. , Dec. 21, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming ...
New Jersey-based Becton, Dickinson and Co. (NYSE:BDX) is considering Mebane and two other locations for a $176 million existing facility expansion expected to create 116 jobs with an average salary of $67,759. On Dec. 17, Alamance County Commissioners voted 4-1 on an incentive grant of $2.6 million to lure the company, which manufacturers and sells medical devices, instrument systems and regents. The Mebane City Council has also approved incentives and waived fees totaling $2.64 million.
FRANKLIN LAKES, N.J., Dec. 20, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of its BD MAX™ enteric viral panel, a molecular diagnostic test for the direct qualitative detection and differentiation of enteric viral pathogens that cause viral gastroenteritis. The company now offers a broad suite of solutions for the detection of intestinal conditions of bacterial, viral, and parasitic origin, in clinically relevant, targeted panels.
Becton, Dickinson and Company (NYSE:BDX) received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to $264.38 at one point, and Read More...